JP2015509368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509368A5 JP2015509368A5 JP2014558920A JP2014558920A JP2015509368A5 JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5 JP 2014558920 A JP2014558920 A JP 2014558920A JP 2014558920 A JP2014558920 A JP 2014558920A JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603622P | 2012-02-27 | 2012-02-27 | |
| US61/603,622 | 2012-02-27 | ||
| PCT/US2013/027580 WO2013130381A1 (en) | 2012-02-27 | 2013-02-25 | Cx3cr1-binding polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509368A JP2015509368A (ja) | 2015-03-30 |
| JP2015509368A5 true JP2015509368A5 (enExample) | 2015-05-07 |
| JP6101715B2 JP6101715B2 (ja) | 2017-03-22 |
Family
ID=47884535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558920A Active JP6101715B2 (ja) | 2012-02-27 | 2013-02-25 | Ｃｘ３ｃｒ１結合ポリペプチド |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US9035029B2 (enExample) |
| EP (2) | EP4050027A3 (enExample) |
| JP (1) | JP6101715B2 (enExample) |
| KR (1) | KR102008136B1 (enExample) |
| CN (3) | CN104245735B (enExample) |
| AP (1) | AP2014007791A0 (enExample) |
| AR (1) | AR090158A1 (enExample) |
| AU (1) | AU2013226340B2 (enExample) |
| CA (1) | CA2862182A1 (enExample) |
| CL (1) | CL2014002072A1 (enExample) |
| EA (1) | EA028183B1 (enExample) |
| EC (1) | ECSP14020402A (enExample) |
| GE (1) | GEP201706773B (enExample) |
| IL (3) | IL291571B2 (enExample) |
| IN (1) | IN2014DN05756A (enExample) |
| MD (1) | MD4548C1 (enExample) |
| MX (1) | MX349192B (enExample) |
| NZ (1) | NZ627260A (enExample) |
| PE (1) | PE20141859A1 (enExample) |
| PH (2) | PH12014501912B1 (enExample) |
| SG (1) | SG11201405283SA (enExample) |
| TN (1) | TN2014000360A1 (enExample) |
| TW (1) | TWI598361B (enExample) |
| UA (1) | UA115781C2 (enExample) |
| UY (1) | UY34644A (enExample) |
| WO (1) | WO2013130381A1 (enExample) |
| ZA (3) | ZA201405021B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| KR102008136B1 (ko) | 2012-02-27 | 2019-08-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｘ3ｃｒ1-결합 폴리펩타이드 |
| EP3035970A1 (en) * | 2013-08-21 | 2016-06-29 | Boehringer Ingelheim International GmbH | Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease |
| RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| EP3325512B1 (en) | 2015-07-23 | 2023-09-06 | Inhibrx, Inc. | Multivalent and multispecific gitr-binding fusion proteins |
| SG11201805422WA (en) | 2016-01-11 | 2018-07-30 | Inhibrx Inc | Multivalent and multispecific ox40-binding fusion proteins |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| KR20230041739A (ko) * | 2016-03-08 | 2023-03-24 | 매버릭 테라퓨틱스, 인크. | 유도성 결합 단백질 및 사용 방법 |
| JP7112735B2 (ja) | 2016-11-29 | 2022-08-04 | 国立研究開発法人国立精神・神経医療研究センター | 進行型免疫性脱髄疾患の予防、発症抑制又は治療剤 |
| WO2018134815A2 (en) * | 2017-01-17 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| IL317013A (en) | 2017-09-08 | 2025-01-01 | Takeda Pharmaceuticals Co | Binding proteins are activated under limited conditions |
| AR114552A1 (es) | 2018-08-13 | 2020-09-16 | Inhibrx Inc | Polipéptidos de unión a ox40 y sus usos |
| JP2022524338A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
| CN110675421B (zh) * | 2019-08-30 | 2022-03-15 | 电子科技大学 | 基于少量标注框的深度图像协同分割方法 |
| WO2022165434A2 (en) * | 2021-02-01 | 2022-08-04 | The General Hospital Corporation | Fc-enhanced antibodies for prevention and treatment of ebola virus infection |
| TW202246334A (zh) * | 2021-02-02 | 2022-12-01 | 美商美國禮來大藥廠 | Gitr拮抗劑及其使用方法 |
| CA3262048A1 (en) | 2022-07-18 | 2024-01-25 | Sanofi Sa | Cx3cr1-binding compounds, methods and uses thereof |
| IL321045A (en) | 2022-12-22 | 2025-07-01 | Chiome Bioscience Inc | Anti-human CX3CR1 antibody |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| AU2000273378A1 (en) * | 2000-02-18 | 2001-08-27 | Millennium Pharmaceuticals, Inc. | Therapeutic methods that target fractalkine or cx3cr1 |
| EP1278767A4 (en) | 2000-04-12 | 2003-11-12 | Principia Pharmaceutical Corp | ALBUMIN FUSED PROTEINS |
| US20020192212A1 (en) | 2001-03-19 | 2002-12-19 | Toshio Imai | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine |
| EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
| JP4123856B2 (ja) | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
| US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20060160076A1 (en) | 2002-06-10 | 2006-07-20 | Meatabolex, Inc. | Methods of treating and diagnosing diabetes with cx3cr1 modulators |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| CN100343304C (zh) | 2002-12-31 | 2007-10-17 | 尼克塔治疗亚拉巴马公司 | 水解稳定的马来酰亚胺封端的聚合物 |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| WO2005103684A2 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1) |
| RU2007117752A (ru) | 2004-10-13 | 2008-11-20 | Аблинкс Н.В. (Be) | Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера |
| WO2006046739A1 (ja) | 2004-10-29 | 2006-05-04 | Eisai R & D Management Co., Ltd. | 炎症性疾患治療剤 |
| EP2479191A3 (en) | 2005-05-18 | 2013-03-13 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
| JP2009504659A (ja) | 2005-08-08 | 2009-02-05 | オンコノン・リミテッド・ライアビリティ・カンパニー | 抗体組成物、腫瘍性疾患の処置方法、および受胎能の調節方法 |
| CA2618482C (en) * | 2005-08-19 | 2014-10-07 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| US20100113339A1 (en) * | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| CN101611056A (zh) | 2006-12-05 | 2009-12-23 | 埃博灵克斯股份有限公司 | 能够结合于血清蛋白的肽 |
| CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| PT2285408T (pt) | 2008-06-05 | 2019-02-01 | Ablynx Nv | Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais |
| WO2010070394A1 (en) | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| WO2011044377A2 (en) | 2009-10-09 | 2011-04-14 | Cell Point, Llc | Chelator-targeting ligand conjugates for cardiovascular imaging |
| EP2486056A1 (en) * | 2009-10-09 | 2012-08-15 | Ablynx N.V. | Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them |
| WO2012078633A2 (en) * | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Methods of inhibiting metastasis from cancer |
| KR102008136B1 (ko) | 2012-02-27 | 2019-08-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｘ3ｃｒ1-결합 폴리펩타이드 |
| EP3035970A1 (en) | 2013-08-21 | 2016-06-29 | Boehringer Ingelheim International GmbH | Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease |
-
2013
- 2013-02-25 KR KR1020147023938A patent/KR102008136B1/ko active Active
- 2013-02-25 IL IL291571A patent/IL291571B2/en unknown
- 2013-02-25 EA EA201400964A patent/EA028183B1/ru not_active IP Right Cessation
- 2013-02-25 PE PE2014001293A patent/PE20141859A1/es active IP Right Grant
- 2013-02-25 SG SG11201405283SA patent/SG11201405283SA/en unknown
- 2013-02-25 EP EP22168124.0A patent/EP4050027A3/en active Pending
- 2013-02-25 MD MDA20140104A patent/MD4548C1/ro not_active IP Right Cessation
- 2013-02-25 AU AU2013226340A patent/AU2013226340B2/en active Active
- 2013-02-25 CN CN201380016996.9A patent/CN104245735B/zh active Active
- 2013-02-25 CN CN202210946091.2A patent/CN115925938A/zh active Pending
- 2013-02-25 IN IN5756DEN2014 patent/IN2014DN05756A/en unknown
- 2013-02-25 AP AP2014007791A patent/AP2014007791A0/xx unknown
- 2013-02-25 US US13/775,307 patent/US9035029B2/en active Active
- 2013-02-25 PH PH1/2014/501912A patent/PH12014501912B1/en unknown
- 2013-02-25 CN CN201810147778.3A patent/CN108610421B/zh active Active
- 2013-02-25 UA UAA201410430A patent/UA115781C2/uk unknown
- 2013-02-25 NZ NZ627260A patent/NZ627260A/en unknown
- 2013-02-25 IL IL311502A patent/IL311502A/en unknown
- 2013-02-25 WO PCT/US2013/027580 patent/WO2013130381A1/en not_active Ceased
- 2013-02-25 GE GEAP201313583A patent/GEP201706773B/en unknown
- 2013-02-25 MX MX2014009864A patent/MX349192B/es active IP Right Grant
- 2013-02-25 CA CA2862182A patent/CA2862182A1/en not_active Abandoned
- 2013-02-25 PH PH1/2021/553014A patent/PH12021553014A1/en unknown
- 2013-02-25 EP EP13709641.8A patent/EP2820046B1/en active Active
- 2013-02-25 JP JP2014558920A patent/JP6101715B2/ja active Active
- 2013-02-26 TW TW102106771A patent/TWI598361B/zh active
- 2013-02-26 AR ARP130100585A patent/AR090158A1/es active IP Right Grant
- 2013-02-27 UY UY0001034644A patent/UY34644A/es unknown
-
2014
- 2014-07-09 ZA ZA2014/05021A patent/ZA201405021B/en unknown
- 2014-08-05 CL CL2014002072A patent/CL2014002072A1/es unknown
- 2014-08-07 IL IL234018A patent/IL234018B2/en unknown
- 2014-08-26 TN TNP2014000360A patent/TN2014000360A1/fr unknown
- 2014-09-25 EC ECIEPI201420402A patent/ECSP14020402A/es unknown
-
2015
- 2015-04-09 US US14/682,131 patent/US9458235B2/en active Active
-
2016
- 2016-08-22 US US15/242,639 patent/US9783612B2/en active Active
-
2017
- 2017-09-29 US US15/720,792 patent/US10385134B2/en active Active
-
2019
- 2019-07-09 US US16/505,773 patent/US11384151B2/en active Active
-
2022
- 2022-06-09 US US17/836,473 patent/US12221487B2/en active Active
-
2023
- 2023-09-19 ZA ZA2023/08845A patent/ZA202308845B/en unknown
- 2023-09-19 ZA ZA2023/08846A patent/ZA202308846B/en unknown